KYKO.F Stock Overview
Engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Kyowa Kirin Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥16.75 |
| 52 Week High | JP¥22.21 |
| 52 Week Low | JP¥15.78 |
| Beta | 0.24 |
| 11 Month Change | -4.30% |
| 3 Month Change | -20.14% |
| 1 Year Change | 4.02% |
| 33 Year Change | -41.81% |
| 5 Year Change | -10.15% |
| Change since IPO | 210.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| KYKO.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | 0.3% |
| 1Y | 4.0% | 10.8% | 31.1% |
Return vs Industry: KYKO.F underperformed the US Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: KYKO.F underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| KYKO.F volatility | |
|---|---|
| KYKO.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KYKO.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KYKO.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,974 | Masashi Miyamoto | www.kyowakirin.com |
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent.
Kyowa Kirin Co., Ltd. Fundamentals Summary
| KYKO.F fundamental statistics | |
|---|---|
| Market cap | US$8.38b |
| Earnings (TTM) | US$540.11m |
| Revenue (TTM) | US$3.23b |
15.5x
P/E Ratio2.6x
P/S RatioIs KYKO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KYKO.F income statement (TTM) | |
|---|---|
| Revenue | JP¥498.98b |
| Cost of Revenue | JP¥128.24b |
| Gross Profit | JP¥370.74b |
| Other Expenses | JP¥287.20b |
| Earnings | JP¥83.54b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 164.12 |
| Gross Margin | 74.30% |
| Net Profit Margin | 16.74% |
| Debt/Equity Ratio | 0% |
How did KYKO.F perform over the long term?
See historical performance and comparison